Guest guest Posted November 6, 2009 Report Share Posted November 6, 2009 This article was updated Feb 6, 2009 and published by Medscape from WEB MD, which has attained a high approval rate from the medical community. It doesn't get much better than this. Membership is free if you have to sign in for information. Print in quotations is incomplete. To read the entire script, go to the website printed below. " Transplantation has been relegated to patients who do not achieve molecular remissions or show resistance to imatinib and failure to second-generation bcr-abl kinase inhibitors such as dasatinib. Mechanisms for resistance to imatinib are: (1) BCR-ABL amplification, and (2) BCR-ABL– independent mechanisms such as: (A) Src family of kinase activation and ( additional molecular events. Previous exposure to imatinib before transplantation does not adversely effect posttransplant outcomes such as overall survival and progression-free survival with 90% engraftment, higher relapsed mortality (24%) and lower graft versus host disease (GVHD) (acute, 42%; chronic, 17%).15 " Treatment decisions involving the use of interferon, BMT, or investigative options for younger patients with chronic myelogenous leukemia (CML) are extremely complex and in constant flux. Individualized decisions should be made in conjunction with consultation with physicians familiar with the recent literature. " http://emedicine.medscape.com/article/199425-treatment FYI, Lottie Duthu Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 6, 2009 Report Share Posted November 6, 2009 Lottie- I fully expect my doctor to one day say....I'd better meet this Lottie someday " - because I'm always bringing in the articles you post. Thank you for keeping us educated. This is a complex disease..a wiley bugger, no? In most cases we are educating our docs- mine didn't know about the gleevec level tests until I told him.  By the way-what does the group think- should we be asking for levels if we are in remission or let sleeping dogs sleep. ________________________________ From: Lottie Duthu <lotajam@...> CML < > Sent: Thu, November 5, 2009 9:45:16 PM Subject: [ ] BMT Info This article was updated Feb 6, 2009 and published by Medscape from WEB MD, which has attained a high approval rate from the medical community. It doesn't get much better than this. Membership is free if you have to sign in for information. Print in quotations is incomplete. To read the entire script, go to the website printed below. " Transplantation has been relegated to patients who do not achieve molecular remissions or show resistance to imatinib and failure to second-generation bcr-abl kinase inhibitors such as dasatinib. Mechanisms for resistance to imatinib are: (1) BCR-ABL amplification, and (2) BCR-ABL– independent mechanisms such as: (A) Src family of kinase activation and ( additional molecular events. Previous exposure to imatinib before transplantation does not adversely effect posttransplant outcomes such as overall survival and progression-free survival with 90% engraftment, higher relapsed mortality (24%) and lower graft versus host disease (GVHD) (acute, 42%; chronic, 17%).15 " Treatment decisions involving the use of interferon, BMT, or investigative options for younger patients with chronic myelogenous leukemia (CML) are extremely complex and in constant flux. Individualized decisions should be made in conjunction with consultation with physicians familiar with the recent literature. " http://emedicine.medscape.com/article/199425-treatment FYI, Lottie Duthu Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.